Standout Papers

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobact... 2023 2026 2024120
  1. Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) (2023)
    Keith S. Kaye, Andrew F. Shorr et al. The Lancet Infectious Diseases

Immediate Impact

52 standout
Sub-graph 1 of 24

Citing Papers

Advances and challenges in portable optical biosensors for onsite detection and point-of-care diagnostics
2024 Standout
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
2024 Standout
1 intermediate paper

Works of Bin Du being referenced

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)
2023 Standout
Serum Levels of Surface Large Envelope Proteins: Prognostic Markers for Hepatitis B e Antigen-Negative Patients with Adefovir Dipivoxil Treatment
2009

Author Peers

Author Last Decade Papers Cites
Bin Du 177 83 50 122 99 34 540
Eyal Braun 232 65 75 93 33 35 641
Anna Sick-Samuels 141 44 68 47 68 39 507
Hisham Ziglam 165 80 43 60 35 30 493
Cumhur Y. Demirkale 167 43 56 94 45 19 468
Marina Esposito‐Farèse 200 44 53 133 40 21 524
Marco Cei 109 98 74 97 68 52 501
Ulrich Jaschinski 348 88 74 44 164 20 635
Fulvia Mazzaferri 183 29 26 106 57 23 602
Elie Saade 162 78 84 115 28 41 592
Travis Jones 405 71 33 28 127 22 639

All Works

Loading papers...

Rankless by CCL
2026